Soligenix, Inc. announced on October 3, 2024, a partnership agreement with Sterling Pharma Solutions to optimize and implement commercially viable, scalable production technology for synthetic hypericin. This active ingredient is crucial for the company's topical drug products, HyBryte™ for cutaneous T-cell lymphoma (CTCL) and SGX302 for psoriasis.
The collaboration focuses on transferring and optimizing manufacturing processes and analytics to enable cGMP (current good manufacturing practice) manufacturing for clinical trials. This move is intended to establish a long-term commercial manufacturing relationship, ensuring future supply.
President and CEO Christopher J. Schaber stated that this partnership aims to scale up the production process and further reduce the cost of goods for synthetic hypericin. This strategic manufacturing advancement is vital as Soligenix progresses its clinical programs toward potential worldwide commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.